How to find the core components of Tisotumab Vedotin-tftv?
Tisotumab Vedotin-tftv is an antibody-drug conjugate (ADC) developed by Genmab and Seagen, targeting tissue factor (TF), a protein that is overexpressed in various solid tumors, including cervical cancer. As a novel therapeutic agent, Tisotumab Vedotin-tftv is designed to deliver a potent cytotoxic payload specifically to tumor cells expressing TF, thereby minimizing toxicity to healthy tissues.
Summary of Research Progress of Tisotumab Vedotin-tftv
The research progress of Tisotumab Vedotin-tftv has been substantial. The drug works by binding to TF on the surface of cancer cells, internalizing the ADC, and releasing the cytotoxic payload within the cell. This mechanism allows for targeted delivery of the drug, enhancing its efficacy while reducing systemic side effects. Tisotumab Vedotin-tftv has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of recurrent or metastatic cervical cancer that has progressed on or after chemotherapy. Globally, the drug is also under review in other regions, with ongoing efforts to secure approvals in additional markets.
The global competition in the ADC market is intense, with several other ADCs targeting various cancers at different stages of development. Key competitors include Roche's Kadcyla (T-DM1) for HER2-positive breast cancer and Seattle Genetics' Adcetris (Brentuximab vedotin) for Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Despite this competition, Tisotumab Vedotin-tftv stands out due to its specific targeting of TF and its potential in treating cervical cancer, a disease area with limited treatment options. Clinical trials have shown promising results, particularly in patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Structural Characteristics of Tisotumab Vedotin-tftv
The overall structural characteristics of Tisotumab Vedotin-tftv are designed to optimize its therapeutic potential. The ADC consists of three main components: the antibody, the linker, and the cytotoxic payload. The antibody is a human IgG1 monoclonal antibody that binds to TF with high affinity and specificity. The linker is a protease-cleavable valine-citrulline (vc) linker that ensures the payload remains attached to the antibody during circulation and is released only upon internalization into the target cell. The cytotoxic payload is monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent.
The selection and advantages of the antibody in Tisotumab Vedotin-tftv are crucial for its effectiveness. The antibody used, known as SPC49, is a human IgG1 monoclonal antibody that binds to TF with high affinity and specificity. TF is a transmembrane protein that plays a role in coagulation and is overexpressed in various solid tumors, including cervical cancer. The high affinity and specificity of SPC49 ensure that the ADC can effectively target and bind to TF-expressing cancer cells, thereby maximizing the delivery of the cytotoxic payload. Additionally, the antibody has been engineered to enhance its stability and reduce immunogenicity, making it suitable for repeated dosing. The high binding affinity and low immunogenicity of the antibody contribute to the overall safety and efficacy of Tisotumab Vedotin-tftv.
The linker in Tisotumab Vedotin-tftv is a key component that ensures the stability of the ADC in circulation and the controlled release of the payload inside the target cell. The linker used is a protease-cleavable valine-citrulline (vc) linker. This linker is stable in the bloodstream but can be cleaved by lysosomal proteases once the ADC is internalized into the cell. This design minimizes the risk of premature release of the cytotoxic payload, which could cause off-target toxicity. The cleavable nature of the linker also allows for the efficient release of the payload within the tumor cell, ensuring maximum therapeutic effect. The linker is designed to maintain the integrity of the ADC during systemic circulation, preventing the payload from being released before reaching the target cells. This stability is crucial for minimizing systemic toxicity and ensuring that the drug reaches its intended target.
The cytotoxic drug payload in Tisotumab Vedotin-tftv is monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. MMAE works by binding to tubulin and disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. MMAE is chosen for its high potency and ability to induce cell death at low concentrations. The payload is linked to the antibody through the cleavable linker, ensuring that it remains inactive during circulation and is only activated once inside the target cell. This design enhances the safety and efficacy of the ADC by minimizing systemic toxicity. MMAE is particularly effective against cancer cells because it targets the microtubules, which are essential for cell division. By disrupting the formation of the mitotic spindle, MMAE prevents cancer cells from completing the cell cycle, leading to cell death. The high potency of MMAE allows for the use of lower doses of the ADC, further reducing the risk of side effects.
Summary and Prospect
In summary, Tisotumab Vedotin-tftv represents a significant advancement in the treatment of cervical cancer, particularly for patients with recurrent or metastatic disease who have progressed on or after chemotherapy. The drug's unique mechanism of action, combined with its optimized antibody, linker, and cytotoxic payload, positions it as a promising therapeutic option. Ongoing clinical trials continue to evaluate its safety and efficacy, and if successful, Tisotumab Vedotin-tftv has the potential to become a standard treatment for cervical cancer, addressing a critical unmet medical need. Future research will focus on expanding its use to other TF-expressing cancers and exploring combination therapies to further enhance its therapeutic benefits. The detailed selection and engineering of the antibody, the stability and cleavability of the linker, and the high potency of the cytotoxic payload all contribute to the overall effectiveness and safety of Tisotumab Vedotin-tftv, making it a promising candidate in the field of targeted cancer therapy.
How to find the the core components of an ADC drug?
In Patsnap Synapse and Patsnap Bio, you can find the sequence and latest research and development advances of all ADC drugs.
Taking Tisotumab Vedotin-tftv as an example, First, you can log in to Patsnap Synapse, enter ' Tisotumab Vedotin-tftv ' in the search box and click to view the details. On the details page, you can find the basic information and research progress of Tisotumab Vedotin-tftv.
After entering the details page, drop down to find the core Structure information of ADC drug and click view Structure in the Linker section to find the structure and type of ADC drug Linker.
The details page also lists the complete sequence information of the antibody part. By clicking on "Find Similar Sequence", you can be redirected to Patsnap Bio to search for similar sequences of the antibody.
Clicking on the sequence name will provide you with all the basic information of that sequence.
Patsnap Bio helps you turn weeks into minutes with cutting-edge AI-enabled tools built to master the complexities of sequence retrieval and automate IP analysis with precision and ease.
